

CITATION REPORT

List of articles citing

SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment

DOI: 10.1136/annrheumdis-2020-217506
Annals of the Rheumatic Diseases, 2020, 79, e61.

Source: <https://exaly.com/paper-pdf/77647571/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
22	Tracking clinical resources for coronavirus disease 2019. <i>Current Opinion in Rheumatology</i> , 2020 , 32, 441-448	5.3	2
21	COVID-19 Pneumonia in Patients on Chronic Hydroxychloroquine Therapy: Three Cases of COVID-19 Pneumonia. <i>Case Reports in Infectious Diseases</i> , 2020 , 2020, 8822753	0.9	3
20	Initial data from the COVID-19 Global Rheumatology Alliance provider registries. <i>Lancet Rheumatology</i> , 2020 , 2, e317	14.2	
19	COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1382-1383	2.4	58
18	Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1386-1388	2.4	56
17	Evidence of Protective Effect of Hydroxychloroquine on COVID-19. <i>Journal of Rheumatology</i> , 2020 , 47, 1587	4.1	4
16	Initial data from the COVID-19 Global Rheumatology Alliance provider registries - Authorsareply. <i>Lancet Rheumatology</i> , 2020 , 2, e317	14.2	6
15	COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1150-1157	5.3	29
14	Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. <i>Expert Review of Clinical Immunology</i> , 2020 , 16, 659-666	5.1	40
13	Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' by Joob and Wiwanitkit. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e62	2.4	9
12	Patients with lupus are not protected from COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e21	2.4	8
11	SLE patients are not immune to covid-19: importance of sending the right message across. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e23	2.4	9
10	No evidence so far on the protective effect of hydroxychloroquine to prevent COVID-19: comment by Joob and Wiwanitkit. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e22	2.4	12
9	Response to: 'Patients with lupus are not protected from COVID-19: a comment' by Sawalha, 'No evidence so far on the protective effect of hydroxychloroquin to prevent COVID-19: response to the Comment by Joob and Wiwanitkit' by Romo and 'SLE patients are not immune to COVID-19: importance of sending the right message across' by Goyal. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e24	2.4	
8	Rheumatic disease and COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	1
7	Trajectories of COVID-19 information in the Annals of the Rheumatic Diseases: the first months of the pandemic. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 26-30	2.4	5
6	Coronavirus disease 2019 (COVID-19) in patients with systemic autoimmune diseases or vasculitis: radiologic presentation. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 51, 339-348	5.1	9

- 5 SARS-CoV-2 Infection and COVID-19 in 5 Patients in Ecuador After Prior Treatment with Hydroxychloroquine for Systemic Lupus Erythematosus. *American Journal of Case Reports*, **2020**, 21, e927304 13 4
- 4 Hydroxychloroquine as a Chemoprophylactic Agent for COVID-19: A Clinico-Pharmacological Review. *Frontiers in Pharmacology*, **2020**, 11, 593099 5.6 4
- 3 COVID-19 Prevalence and Outcomes among Individuals with Rheumatoid Arthritis and Systemic Lupus Erythematosus Taking Hydroxychloroquine; A Retrospective Analysis. *Open Rheumatology Journal*, **2021**, 15, 69-76 0.2 1
- 2 Chloroquine, Hydroxychloroquine, Retinal Toxicity, and COVID-19. *Asia-Pacific Journal of Ophthalmology*, **2020**, 9, 374 3.5
- 1 Hydroxycloquine for Pre-Exposure Prophylaxis for SARS-COV-2.